



CryoLife Declares a Dividend of Approximately \$0.75 Per Share on Its Convertible Preferred Stock

December 5, 2006

ATLANTA, Dec. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that the Company has declared a dividend of approximately \$0.75 per share on its 6% convertible preferred stock, payable on January 2, 2007, to shareholders of record as of the close of business on December 22, 2006.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web site: <http://www.cryolife.com>

Media Contacts:

D. Ashley Lee
Executive Vice President, Chief Financial Officer and
Chief Operating Officer
Phone: 770-419-3355

Katie Brazel
Fleishman Hillard
Phone: 404-739-0150

SOURCE CryoLife, Inc.
Web site: <http://www.cryolife.com>
(CRY)